With the continuous popularization of smart phones, the saturation trend of 4G market has emerged. The landing of 5G commercial will drive the development of 5G mobile phones and bring new vitality to the mobile phone industry. IiMedia Research (AI Media Consulting) data show that it is expected that there will be a change of 5G mobile phones in 2020-2023, and the global shipment of 5G smart phones will increase to 401.3 million units in 2023. At present, Huawei, VO, Xiaomi and other Chinese mobile phone brands have all taken part in the 5G market battle. In addition, 5G mobile phones will further drive the development of the upstream and downstream of the industrial chain. The upstream component manufacturers, the middle-stream communication equipment manufacturers and the downstream terminal manufacturers will all benefit. It is estimated that the market size of 5G related products and services will reach 1.15 trillion yuan in 2025. Ai Mei's consulting analysts believe that under the background of favorable policies, economic prosperity, technological development and expanding social demand, the 5G mobile phone industry will accelerate its development. Players with strong technological and economic strength are expected to become track leaders and the head effect of the industry will gradually become prominent.
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.